


**Claims:**

1. Use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino]phenyl]-benzamide of the formula I



(I)

or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for the treatment of a pulmonary fibrosis disease.

2. The use according to claim 1, wherein the pulmonary fibrosis disease is an interstitial lung disease.

3. The use according to claim 1, wherein the pulmonary fibrosis disease is an idiopathic pulmonary fibrosis.

4. Use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino]phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof in the treatment of pulmonary fibrosis.

5. A method of treating a human subject suffering from pulmonary fibrosis which comprises administering to a said human in need of such treatment a dose, effective against pulmonary fibrosis, of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino]phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof.

6. Use according to any one of claims 1 to 4 or method according to claim 5 wherein the pulmonary fibrosis is induced by asbestos.

7. A method of administering to a human subject suffering from pulmonary fibrosis which comprises administering a pharmaceutically effective amount of 4-(4-methylpiperazin-1-

ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof to said human subject once daily for a period exceeding 3 months.

8. Use or method according to any one of claims 1 to 7 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is in the form of a pharmaceutically acceptable acid addition salt thereof.

9. Use or method according to claim 8 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is in the monomethane sulfonate salt form thereof.

10. Use or method according to claim 9 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is in the beta crystal form of the mesylate salt.

11. Use or method according to claim 11 wherein a daily dose of a monomethanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I in the beta crystal form corresponding to 200 to 800 mg of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I free base is administered to an adult human.